apraclonidine (Iopidine)

09/01/2006 - "Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination."
05/15/2017 - "Apraclonidine is not only useful as a diagnostic test in Horner's syndrome, but may be an effective and safe treatment for BoNT-induced ptosis."
09/01/2006 - "The application of apraclonidine in pediatric patients is safe and effective in the diagnosis of Horner syndrome. "
06/01/2006 - "The application of 0.5% apraclonidine in pediatric patients is safe and effective in the diagnosis of Horner syndrome."
12/15/2020 - "The goal of this study was to describe the use of apraclonidine in the diagnosis of acute Horner syndrome in patients with an unequivocal onset within 7 days. "

10/01/1997 - "This study describes our long-term experience with apraclonidine 0.5% in the treatment of chronic glaucoma in clinical practice. "
12/01/1995 - "To evaluate the effect of the chronic use of apraclonidine 0.5% on the intraocular pressure (IOP) of patients with glaucoma; also, to study the side effect profile of this drug when used chronically. "
06/01/2009 - "In all, 115 eyes of 75 pediatric glaucoma patients received apraclonidine 0.5% drops, for a total 179 treatment sessions. "
06/01/2009 - "Here we evaluate the safety of topical apraclonidine 0.5% when used in children with glaucoma. "
06/01/2009 - "We have used topical apraclonidine 0.5% to treat infants and small children with glaucoma undergoing angle surgery, and selected children needing additional IOP reduction. "

04/01/1999 - "Apraclonidine 0.5% appears to be effective in reduction of post-dilated IOP increases in patients with chronic open-angle glaucoma."
04/01/1999 - "The purpose of this study is to determine the effectiveness of 0.5% apraclonidine in reversing IOP increases after pupillary dilation in patients with chronic open-angle glaucoma. "
11/01/1997 - "This study consisted of 231 consecutive eyes of patients with primary open-angle glaucoma undergoing ALT: 70 eyes (30%) were started on a regimen including chronic apraclonidine 0.5% use (group A) and 161 eyes (70%) were started on a regimen without chronic apraclonidine 0.5% use (group B). "
04/01/1999 - "Apraclonidine 1.0% has been shown to reverse the potential intraocular pressure (IOP) increase after pupil dilation IOP increases in patients with chronic open-angle glaucoma. "
04/01/1999 - "Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma."

04/01/2012 - "No differences were observed between the preoperative [0.40 (SD 0.07)] and 1-month basal values [0.38 (SD 0.07)], and instillation of apraclonidine no longer induced a hypersensitivity response. "
06/01/2000 - "Forty-five patients were identified with a significant allergic reaction to apraclonidine that resulted in drug discontinuation. "
06/01/2000 - "A retrospective chart review was performed to identify patients who had demonstrated an allergic reaction to apraclonidine of sufficient severity to result in drug discontinuation. "
01/01/1998 - "For the 10 patients rechallenged with apraclonidine, the mean time to allergy was 13.6 +/- 10.2 days (range 3-32 days). "
01/01/1998 - "The mean time to apraclonidine allergy from initial exposure was 12.9 +/- 12.9 months (range 2.1-46.8 months). "

01/01/2020 - "The change in gas bubble volume over time was calculated in an eye with normal aqueous outflow, ocular hypertension (OHT), and OHT with apraclonidine treatment. "
04/01/1999 - "We studied the acute effects of the ocular hypotensive drug, apraclonidine (AP), on intraocular pressure (IOP) and aqueous humor dynamics of anesthetized rats during infusion-induced ocular hypertension. "
09/01/1993 - "Apraclonidine effectively lowers IOP associated with open-angle glaucoma or ocular hypertension; these pilot results will need to be confirmed by a larger pivotal study. "
07/01/1991 - "The short-term additive effect and side effects of adding 1% apraclonidine hydrochloride to nonselective beta-blockers were investigated in 21 patients with ocular hypertension or early primary open-angle glaucoma. "
10/01/1991 - "Seventeen patients (15 with primary open-angle glaucoma, 1 with pigmentary glaucoma, and 1 glaucoma suspect) on long-term timolol treatment in both eyes received a single dose of apraclonidine in one eye and a placebo in the other. "